Traders Sell Bristol-Myers Squibb (BMY) on Strength (BMY)

Investors sold shares of Bristol-Myers Squibb Co (NYSE:BMY) on strength during trading hours on Monday. $148.92 million flowed into the stock on the tick-up and $276.79 million flowed out of the stock on the tick-down, for a money net flow of $127.87 million out of the stock. Of all companies tracked, Bristol-Myers Squibb had the 4th highest net out-flow for the day. Bristol-Myers Squibb traded up $0.93 for the day and closed at $46.50

BMY has been the topic of several research reports. Zacks Investment Research lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Wednesday, January 16th. ValuEngine lowered shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research note on Friday, January 4th. Bank of America set a $53.00 price target on shares of Bristol-Myers Squibb and gave the company a “hold” rating in a research note on Friday, January 25th. BMO Capital Markets restated a “buy” rating and issued a $59.00 price target on shares of Bristol-Myers Squibb in a research note on Tuesday, February 19th. Finally, Societe Generale upgraded shares of Bristol-Myers Squibb from a “sell” rating to a “buy” rating in a research note on Tuesday, January 15th. One equities research analyst has rated the stock with a sell rating, twelve have issued a hold rating and six have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $59.13.

The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.50 and a current ratio of 1.61. The firm has a market cap of $75.25 billion, a PE ratio of 11.68, a P/E/G ratio of 2.37 and a beta of 0.79.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, January 24th. The biopharmaceutical company reported $0.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.85 by $0.09. The business had revenue of $5.97 billion during the quarter, compared to analysts’ expectations of $5.95 billion. Bristol-Myers Squibb had a net margin of 21.95% and a return on equity of 48.99%. The business’s revenue was up 9.6% on a year-over-year basis. During the same period last year, the firm posted $0.68 earnings per share. Sell-side analysts expect that Bristol-Myers Squibb Co will post 4.16 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 1st. Stockholders of record on Friday, April 5th will be issued a $0.41 dividend. This represents a $1.64 annualized dividend and a dividend yield of 3.53%. The ex-dividend date is Thursday, April 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently 41.21%.

Institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in Bristol-Myers Squibb by 1.0% during the third quarter. Vanguard Group Inc. now owns 128,376,159 shares of the biopharmaceutical company’s stock worth $7,969,593,000 after buying an additional 1,229,553 shares in the last quarter. Vanguard Group Inc boosted its holdings in Bristol-Myers Squibb by 1.0% during the third quarter. Vanguard Group Inc now owns 128,376,159 shares of the biopharmaceutical company’s stock worth $7,969,593,000 after buying an additional 1,229,553 shares in the last quarter. BlackRock Inc. boosted its holdings in Bristol-Myers Squibb by 0.9% during the fourth quarter. BlackRock Inc. now owns 115,573,078 shares of the biopharmaceutical company’s stock worth $6,007,489,000 after buying an additional 999,193 shares in the last quarter. Dodge & Cox boosted its holdings in Bristol-Myers Squibb by 0.8% during the third quarter. Dodge & Cox now owns 32,969,186 shares of the biopharmaceutical company’s stock worth $2,046,727,000 after buying an additional 264,100 shares in the last quarter. Finally, Northern Trust Corp boosted its holdings in Bristol-Myers Squibb by 4.4% during the fourth quarter. Northern Trust Corp now owns 22,576,884 shares of the biopharmaceutical company’s stock worth $1,173,547,000 after buying an additional 954,877 shares in the last quarter. Institutional investors and hedge funds own 74.27% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Traders Sell Bristol-Myers Squibb (BMY) on Strength (BMY)” was first reported by Transcript Daily and is the property of of Transcript Daily. If you are reading this piece of content on another domain, it was stolen and reposted in violation of US & international trademark & copyright laws. The correct version of this piece of content can be viewed at https://transcriptdaily.com/2019/04/16/traders-sell-bristol-myers-squibb-bmy-on-strength-bmy.html.

Bristol-Myers Squibb Company Profile (NYSE:BMY)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Recommended Story: Do closed-end mutual funds pay dividends?

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.